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Objectives: To compare platelet indices in preeclamptic and normotensive pregnants and to 
investigate the clinical use of these parameters in preeclampsia prediction. 
Material and methods: This retrospective case- control study included 257 preeclampsia 
patients and 264 healthy pregnant women as the control group. The groups were compared in 
terms of platelet count (PC), mean platelet volume (MPV), platelet distribution range (PDW), 
plateletcrit (Pct), Pct / MPV ratio and PC / MPV ratio.  
Results: Between the preeclampsia group and the control group; mean platelet count (227.22 
± 78.58 vs 236.69 ± 64.30), plateletcrit (PCT) (0.21 ± 0.06 vs 0.24 ± 0.27), and platelet 
distribution width (PDW) (17.11 ± 0.80 vs 17.29 ± 0.82) were not significantly different (p> 
0.05). However, MPV values were significantly higher in the preclampsia group compared to 
the control group (9.66 ± 1.62 and 8.92 ± 1.33, respectively) (p < 0.001). In our study, the 
optimum cut-off value of MPV was 9.15 with 58.7% sensitivity and 61.7% specificity for the 
prediction of preeclampsia. Pct/MPV ratio (0.02 ± 0.007 vs 0.027 ± 0.029) ( p = 0.01) and 
PC/MPV ratio ( 24.63 ± 10.90 vs 27.63 ± 10.24) (p = 0.001) were significantly lower in the 
preeclampsia group than in the control group. 
Conslusions: In preeclampsia, changes in platelet functions, destruction and production lead 
to changes in platelet indices. Compared with normal healthy pregnant women, preeclamptic 
pregnant women have higher MPV values. In preeclampsia prediction, MPV and PC/MPV 
ratio are promising as a diagnostic parameter. 
 




 Preeclampsia is a multifactorial and multisystemic disease characterized by high 
blood pressure and proteinuria after 20 weeks of gestation. Preeclampsia, which has an 
important role in maternal morbidity and mortality, differs geographically and affects 5–8% 
of all pregnancies [1, 2]. Although its pathophysiology is still unclear, hemostatic changes 
such as endothelial cell damage, platelet activation, increased intravascular thrombin 
formation have been known to be the main events in the pathophysiology of preeclampsia [3]. 
 In normal pregnancy, a small increase in platelet aggregation is observed, which is 
compensated by increased platelet synthesis. Mean platelet volume (MPV) also increases due 
to increased platelet synthesis [4, 5]. Preeclampsia which is characterized by endothelial 
damage; uncontrolled intravascular platelet activation and increased platelet destruction are 
expected outcome [6]. Decrease in platelet count stimulates new platelet synthesis in the bone 
marrow and releases young and large platelets into the circulation [7]. 
 
 The role of platelets in the pathophysiology of preeclampsia and therefore MPV 
values may vary in preeclampsia. The aim of this study was to evaluate whether MPV and 
PC/MPV ratio, which can be detected in a simple whole blood count, have a place in clinical 
practice in predicting preeclampsia. 
 
MATERIAL AND METHODS 
 
 This retrospective study included 521 patients admitted to the Gynecology and 
Obstetrics Clinic of our hospital between 2018 and 2019, a tertiary center with 12000 
deliveries annualy. The study complies with the Declaration of Helsinki. This study was 
approved by Bursa Yuksek Ihtisas Ethics Committee (2011-KAEK-25 2020/02-18). In our 
institute, which is a training and research hospital, a general informed consent from patient 
admission is used in retrospective studies. The patients were divided into two groups as 264 
healthy normotensive pregnant women and 257 preeclampsia patients with no medical or 
obstetric problems other than preeclampsia. Preeclampsia was diagnosed according to the 
American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin [8]. In a 
patient whose blood pressure was normal previously; systolic blood pressure > 140 mmHg, 
diastolic blood pressure > 90 mmHg in two separate measurements made at least six hours 
and marked proteinuria (urinary protein excretion > 300 mg/24 h), after 20th gestational week 
were diagnostic criteria. 
 Women with systemic disease (hypertension, endocrinological pathology, diabetes 
mellitus, heart disease, renal disease, liver disease), gestational diabetes mellitus, morbid 
obesity (BMI ≥ 40 kg/m2), history of thromboembolism or known thrombophilic disease, 
anticoagulant use, malformed fetus and multiple pregnancies, 'hemolysis, increased liver 
function enzymes and low platelet count' (HELLP) syndrome were excluded from the study. 
 
Statistical Analysis 
 In the descriptive statistics of the data; mean, standard deviation, median, min-max, 
ratio and frequency values were used. The distribution of the variables was checked by 
Kolmogorov-Simirnov test. Independent sample t-test (two-tailed) was used for data analysis. 




 Table 1 presents the maternal demographic characteristics and delivery outcomes of 
both groups. The ages of the patients in the preeclampsia group (33.02 ± 5.82/26.77 ± 6.09; p 
< 0.001) and body mass index (BMI) (33.02 ± 5.82/29.75 ± 4.92; p < 0.001) were 
significantly higher than the control group. While there was no significant difference between 
gravida and parity numbers, the gestational week at birth (34.81 ± 3.76/38.36), 99; p < 0.001), 
birth weight of infants (2464 ± 947/3229 ± 573; p < 0.001) and 1st minute (8.35 ± 1.63/8.82 ± 
0.84; p < 0.001) and 5th minute (9.28 ± 1.67/9.75 ± 0.82; p < 0.001) APGAR scores were 
significantly lower in the preeclampsia group than in the control group. 
 Table 2 contains laboratory data containing the platelet indices in detail. When the 
groups were evaluated in terms of whole blood count parameters; white blood cell (WBC), 
hemoglobin (hb), hematocrit (hct), platelet count (PC), platelet distribution range (PDW), 
plateletcrit (Pct) values were not significantly different; only mean platelet volume (MPV) 
values were significantly higher in the preeclampsia group (9.66 ± 1.62/8.92 ± 1.33; p < 
0.001). Also in the preeclampsia group; the Pct/MPV ratio (0.02 ± 0.007 vs 0.027 ± 0.029) (p 
= 0.01) and the PC/MPV ratio (24.63 ± 10.90 vs 27.63 ± 10.24) (p = 0.001), which were 
simply calculated using these indices, were observed significantly lower than the control 
group.  
 
Binary Logistic Regression Analysis 
Results of the logistic regression analysis are shown in Table 3. In unadjusted model, 
increased MPV and BMI, ALT, BUN levels were significantly associated with high odds of 
having preeclampsia. 
 
Receiver Operating Characteristic (ROC) Curve Analysis 
The ROC curve for MPV for predicting the preeclampsia risk is shown in Figure 1. 
The area under the ROC curves were 0.634 (95% CI 0.587–0.682, p < 0.001) for MPV. The 
optimal cut-off value of MPV for detecting preeclampsia was ≥ 9.15 ng/mL, at which the 
sensitivity is 58.7% and specificity is 61.7%. 
DISCUSSION 
 
There are two consecutive steps in the pathogenesis of preeclampsia. In the first step, 
utero-placental arterial blood flow decreases and hypoxia develops due to insufficient 
invasion of cytotrophoblasts to the uterine wall at the maternofetal junction. Released free 
oxygen radicals cause placental dysfunction, release of anti-angiogenic factors of 
proinflammatory cytokines, and activation of neutrophils [9, 10]. In the second step, activated 
neutrophils infiltrate maternal vascular tissue and PE starts; platelet activation, 
vasoconstriction, endothelial dysfunction and end-organ ischemia occur [11]. As a result of all 
this; PE is clinically presented with hypertension, proteinuria, edema, headache, 
coagulopathy, renal and hepatic dysfunction. [9, 12].  
MPV is being studied with increasing interest as a potential marker for the prediction 
of preeclampsia, since it is easily detectable during complete blood count and reflects indirect 
platelet reactivity. In our study, MPV value was significantly higher in preeclamptic 
pregnants in the third trimester compared to normotensive pregnants. There are many studies 
showing that MPV value increases especially in the 2nd and 3rd trimesters in preeclampsia 
[11, 13–20].  
These studies suggest that disruption of the microcirculation in the cascade beginning 
with endothelial damage in preeclampsia leads to microtrombus formation, and that platelet 
count decreases with increasing platelet destruction, and the increase in MPV values of 
younger and larger platelets as a result of stimulation of platelet production in the bone 
marrow reflects the increase in MPV values. However, in our study; similar to the results of 
the study in which Dündar and et al. [21], evaluated the platelet parameters longitudinally in 
preeclamptic and normotensive pregnancies during the course of pregnancy, an increase in 
MPV was observed without a decrease in platelet count. In preeclamptic pregnants; while the 
number of platelets does not change, the number of studies advocating an increase in MPV is 
not small [22, 23]. MPV was found to be high in many cases with vascular risk such as 
diabetes mellitus, hypercholesterolemia, and acute myocardial infarction that did not 
associated with thrombocytopenia [24]. In preeclampsia, the interaction between damaged 
endothelial cells and platelets may disrupt the coagulation process, or large and enzymatically 
active platelets may have a different role in the pathogenesis of preeclampsia. 
 To date, the results of studies examining the relationship between preeclampsia and 
MPV value are conflicting. In addition to numerous studies saying that MPV increases in 
preeclampsia, there are studies reporting that MPV value decreases [25] or MPV value does 
not change, and there is no predictive value [5, 26]. Although these differences are related to 
the analysis method used, the anticoagulant used, the time taken for analysis, factors such as 
study design and number of patients included may also be effective [7]. 
 In our study, the optimum cut-off value of MPV for preeclampsia prediction was 
found to be ≥ 9.15 with 58.7% sensitivity and 61.7% specificity (area under the ROC curve 
0.634, p < 0.001, 95% Confidence Interval). This value is indicated by Manneerts and his 
colleagues (16) as 8.15. In the literature, the cut-off values calculated for MPV in 
preeclampsia prediction ranged between 8.65 and 9.95. [27, 28] 
 Studies emphasize that platelet indices should not be ignored when evaluating 
complete blood count. Doğan et al., reported that the risk of developing PE increased by two-
fold in patients with platelet counts ≤ 190 * 109/L, two-fold in patients with MPV ≥ 9 fL, and 
2.4 fold in patients with PC/MPV ratio ≤ 19.9, but stated that changes in platelet indices were 
not associated with PE severity [17]. AlSheeha et al. [25], reported that in preeclamptic 
pregnants, platelet count decreased while MPV did not change. In our study, on the contrary, 
platelet count did not decrease significantly in PE, whereas MPV was found to be 
significantly higher and ironically, both studies concluded that PC/MPV ratio decreased 
significantly in preeclampsia. 
 In our study, the birth weeks of preeclamptic pregnant women, birth weight of 
infants, and APGAR scores of 1 and 5 minutes were significantly lower. PE is associated with 
preterm birth and low birth weight [27, 29]. Early recognition should be a primary goal for the 
prevention of preeclampsia. However, some studies reported that the first trimester MPV 
value and a meta-analysis showed that the first and second trimester MPV values were not 
significant in PE prediction [21, 31]. 
 With the MPV value to be evaluated in the third trimester, the follow-up of the 
pregnants who are predicted to develop PE can be increased and the progression of severe 
preeclampsia, eclampsia and HELLP with high morbidity and mortality can be reduced and 
neonatal care conditions can be ensured. The limitations of this study were its retrospective 




 In our study, MPV, one of the parameters of complete blood count, which can be 
evaluated as easy, fast and inexpensive in every hospital, was found to be increased in 
preeclampsia. In prenatal follow-up, evaluating MPV value and PC/MPV ratio may be useful 
in the prediction of preeclampsia. 
 Prospective, multicenter, large-scale studies are needed to understand the role of 
platelets in preeclampsia and to reduce maternal and fetal complications. 
Conflict of Interest 
The authors declare that there are no conflicts of interest 
Acknowledgements 
All the authors have approved the manuscript and declare no conflicts of interest. This study 
did not receive any specific grant from any funding agency in the public, commercial or not-
for-profit sector.  
REFERENCES 
1.  Williams ML. Long-term hospitalization of women with high-risk pregnancies. A 
nurse's viewpoint. J Obstet Gynecol Neonatal Nurs. 1986; 15(1): 17–21, doi: 
10.1111/j.1552-6909.1986.tb01362.x, indexed in Pubmed: 3632996. 
2. Young B, Levine R, Karumanchi S. Pathogenesis of Preeclampsia. Annual Review of 
Pathology: Mechanisms of Disease. 2010; 5(1): 173–192, doi: 10.1146/annurev-
pathol-121808-102149. 
3. Romero R, Lockwood C, Oyarzun E, et al. Toxemia: new concepts in an old disease. 
Semin Perinatol. ; 12: 302–323. 
4. Tygart SG, McRoyan DK, Spinnato JA, et al. Longitudinal study of platelet indices 
during normal pregnancy. Am J Obstet Gynecol. 1986; 154(4): 883–887, doi: 
10.1016/0002-9378(86)90476-x, indexed in Pubmed: 3963077. 
5. Ceyhan T, Beyan C, Başer I, et al. The effect of pre-eclampsia on complete blood 
count, platelet count and mean platelet volume. Ann Hematol. 2006; 85: 320. 
6. Stubbs TM, Lazarchick J, Van Dorsten JP, et al. Evidence of accelerated platelet 
production and consumption in nonthrombocytopenic preeclampsia. Am J Obstet 
Gynecol. 1986; 155(2): 263–265, doi: 10.1016/0002-9378(86)90803-3, indexed in 
Pubmed: 3740135. 
7. Kanat-Pektas M, Yesildager U, Tuncer N, et al. Could mean platelet volume in late 
first trimester of pregnancy predict intrauterine growth restriction and pre-eclampsia? 
J Obstet Gynaecol Res. 2014; 40(7): 1840–1845, doi: 10.1111/jog.12433, indexed in 
Pubmed: 25056460. 
8. ACOG Practice Bulletin No. 33: Diagnosis and Management of Preeclampsia and 
Eclampsia. Obstetrics & Gynecology. 2002; 99(1): 159–167, doi: 10.1097/00006250-
200201000-00028. 
9. Steegers E, Dadelszen Pv, Duvekot J, et al. Pre-eclampsia. The Lancet. 2010; 
376(9741): 631–644, doi: 10.1016/s0140-6736(10)60279-6. 
10. Saftlas AF, Beydoun H, Triche E. Immunogenetic determinants of preeclampsia and 
related pregnancy disorders: a systematic review. Obstet Gynecol. 2005; 106(1): 162–
172, doi: 10.1097/01.AOG.0000167389.97019.37, indexed in Pubmed: 15994633. 
11. Yucel B, Ustun B. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean 
platelet volume, red cell distribution width and plateletcrit in preeclampsia. Pregnancy 
Hypertens. 2017; 7: 29–32. 
12. Laresgoiti-Servitje E, Gómez-López N, Olson DM. An immunological insight into the 
origins of pre-eclampsia. Hum Reprod Update. 2010; 16(5): 510–524, doi: 
10.1093/humupd/dmq007, indexed in Pubmed: 20388637. 
13. Hutt R, Ogunniyi SO, Sullivan MH, et al. Increased platelet volume and aggregation 
precede the onset of preeclampsia. Obstet Gynecol. 1994; 83(1): 146–149, indexed in 
Pubmed: 8272297. 
14. Kurtoglu E, Kokcu A, Celik H, et al. Validity of platelet indices in predicting the risk 
of developing preeclampsia. J Exp Clin Med. 2016; 33(2): 57–61. 
15. Yang SW, Cho SH, Kwon HS, et al. Significance of the platelet distribution width as a 
severity marker for the development of preeclampsia. Eur J Obstet Gynecol Reprod 
Biol. 2014; 175: 107–111, doi: 10.1016/j.ejogrb.2013.12.036, indexed in Pubmed: 
24502873. 
16. Mannaerts D, Heyvaert S, De Cordt C, et al. Are neutrophil/lymphocyte ratio (NLR), 
platelet/lymphocyte ratio (PLR), and/or mean platelet volume (MPV) clinically useful 
as predictive parameters for preeclampsia? J Matern Fetal Neonatal Med. 2019; 32(9): 
1412–1419, doi: 10.1080/14767058.2017.1410701, indexed in Pubmed: 29179639. 
17. Doğan K, Guraslan H, Senturk MB, et al. Can Platelet Count and Platelet Indices 
Predict the Risk and the Prognosis of Preeclampsia? Hypertens Pregnancy. 2015; 
34(4): 434–442, doi: 10.3109/10641955.2015.1060244, indexed in Pubmed: 
26362129. 
18. Han L, Liu X, Li H, et al. Blood coagulation parameters and platelet indices: changes 
in normal and preeclamptic pregnancies and predictive values for preeclampsia. PLoS 
One. 2014; 9(12): e114488, doi: 10.1371/journal.pone.0114488, indexed in Pubmed: 
25464515. 
19. Freitas LG, Alpoim PN, Komatsuzaki F, et al. Preeclampsia: are platelet count and 
indices useful for its prognostic? Hematology. 2013; 18(6): 360–364, doi: 
10.1179/1607845413Y.0000000098, indexed in Pubmed: 23676885. 
20. Moraes D, Munhoz TP, Pinheiro da Costa BE, et al. Immature platelet fraction in 
hypertensive pregnancy. Platelets. 2016; 27(4): 333–337, doi: 
10.3109/09537104.2015.1101060, indexed in Pubmed: 26587995. 
21. Dundar O, Yoruk P, Tutuncu L, et al. Longitudinal study of platelet size changes in 
gestation and predictive power of elevated MPV in development of pre-eclampsia. 
Prenat Diagn. 2008; 28(11): 1052–1056, doi: 10.1002/pd.2126, indexed in Pubmed: 
18973157. 
22. Sezer S, Küçük M, Yüksel H, et al. Preeklamptik gebelerde trombosit parametreleri. 
Pam Tıp Derg. 2011; 4(2): 66–71. 
23. Makuyana D, Mahomed K, Shukusho FD, et al. Liver and kidney function tests in 
normal and pre-eclamptic gestation--a comparison with non-gestational reference 
values. Cent Afr J Med. 2002; 48(5-6): 55–59, indexed in Pubmed: 12971159. 
24. Bath P, Butterworth RJ. Platelet size. Blood Coagulation & Fibrinolysis. 1996; 7(2): 
157–161, doi: 10.1097/00001721-199603000-00011. 
25. AlSheeha MA, Alaboudi RS, Alghasham MA, et al. Platelet count and platelet indices 
in women with preeclampsia. Vasc Health Risk Manag. 2016; 12: 477–480, doi: 
10.2147/VHRM.S120944, indexed in Pubmed: 27920548. 
26. Saleh AA, Bottoms SF, Farag AM, et al. Markers for endothelial injury, clotting and 
platelet activation in preeclampsia. Arch Gynecol Obstet. 1992; 251(3): 105–110, doi: 
10.1007/BF02718370, indexed in Pubmed: 1605673. 
27. Mouna K, Doddagowda SM, Junjegowda K, et al. Changes in Haematological 
Parameters in Newborns Born to Preeclamptic Mothers - A Case Control Study in a 
Rural Hospital. J Clin Diagn Res. 2017; 11(7): EC26–EC29, doi: 
10.7860/JCDR/2017/29137.10303, indexed in Pubmed: 28892906. 
28. Jacquemyn Y, Zemtsova O. Risk factors and prediction of preeclampsia. Acta Clin 
Belg. 2010; 65(1): 1–12, doi: 10.1179/acb.2010.001, indexed in Pubmed: 20373592. 
29. Zupan-Simunek V. [Prognosis in newborns after mother's preeclampsia]. Ann Fr 
Anesth Reanim. 2010; 29(5): e135–e139, doi: 10.1016/j.annfar.2010.03.013, indexed 
in Pubmed: 20478688. 
30. Bellos I, Fitrou G, Pergialiotis V, et al. Mean platelet volume values in preeclampsia: 
A systematic review and meta-analysis. Pregnancy Hypertens. 2018; 13: 174–180, doi: 
























Table 1.  Basic demographic and clinical datas 
 















Age 26.77 ± 6.09 30.23 ± 6.52 < 0.001 
BMI* 29.75 ± 4.92 33.02 ± 5.82 < 0.001 
Gravidas 2.39 ± 1.50 2.58 ± 1.59 0.162 
Parity 1.09 ± 1.2 1.13 ± 1.24 0.690 
Gestastional age 38.36 ± 1.99 34.81 ± 3.76 < 0.001 
Birth weigth 3229 ± 573 2464 ± 947 < 0.001 
Fetal length 50.05 ± 2.60 46.04 ± 5.89 < 0.001 
Fetal head 
circumference 
34.53 ± 1.68 32.41 ± 3.47 < 0.001 
Cyistolic blood  
pressure 
108.02 ± 12.13 155.76 ± 13.98 < 0.001 
Diastolic blood  
pressure 
64.90 ± 9.27 98.39 ± 9.34 < 0.001 
APGAR 1th minute 8.82 ± 0.84 8.35 ± 1.63 < 0.001 
APGA 5th minute 9.75 ± 0.82 9.28 ± 1.67 < 0.001 
































Blood urea nitrogen 
(mg/dL) 
7.92 ± 2.38 11.28 ± 5.04 < 0.001 










11.19 ± 5.78 24.97 ± 39.00 < 0.001 
White blood cel l 
(WBC) (mcL) 
10.82 ± 2.94 11.21 ± 3.30 0.155 
Hemoglobine ( Hb) 
(g/dL) 
11.46 ± 1.27 11.70 ± 1.44 0.045 
Hematocrite (Htc ) 
(%) 
34.98 ± 3.36 35.35 ± 4.01 0.257 
Platelets (PLT) (mcL) 236.69 ± 64.30 227.22 ± 78.58 0.133 
Plateletcrite (PCT) 
(%) 
0.24 ± 0.27 0.21 ± 0.06 0.093 
Red cell distribution 
width (RDW) (%) 
15.36 ± 2.50 15.42 ± 2.70 0.813 
Platelet distribution 
width (PDW) (%) 
17.29 ± 0.82  17.11 ± 0.80 0.014 
Mean platelet volume  
(MPV) (fL) 
8.92 ± 1.33 9.66 ± 1.62 < 0.001 
Mean cell  volume 
(MCV) (fL) 
83.53 ± 7.16 83.82 ± 7.35 0.651 
PLT/MPV 27.63 ± 10.24 24.63 ± 10.90 0.001 
PCT/MPV 0.027 ± 0.029 0.02 ± 0.007 0.01 
Table 3. Evaluation of the association between of MPV and age, BMI, ALT,BUN in the study 
population (women with and without preeclampsia) using the Binary logistic regression 
analysis 
 OR            95% CI p 
  lower upper  
Variables     
Age 1.046 1.011 1.083   0.009 
BMI 1.140 1.091 1.191 < 0.001 
MPV 1.494 1.275 1.751 < 0.001 
ALT 1.074 1.040 1.108 < 0.001 
BUN 1.275 1.183 1.374 < 0.001 
 





Figure 1. Receiver operating characteristic (ROC) curve for MPV for the prediction of 
preeclampsia. The estimate of the area under the ROC curve and its 95% confidence interval 
is shown. Cut-off value of MPV was ≥ 9.15 (sensitivity 58.7% and specificity 61.7%) for 
prediction of preeclampsia. AUC, area under curve. A p value of < 0.05 was considered 
significant (*) 
 
 
 
 
 
 
 
